Hiring in life sciences? Share your open positions with our professional community. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Safety and Feasibility of Reduced-Frequency Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study.

Created on 24 Oct 2026

Authors

Nosha Farhadfar, Maria Sola Soto, Saurabh Chhabra, Valkal Bhatt, Emily Helen Andersen, Zhenyi Xue, Zachariah DeFilipp

Published in

Blood advances. Oct 23, 2026. Epub Oct 23, 2026.

PMID:
42913434
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Sign in to post a review. Add review
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement